Evidence map›Paper›PMID 31359276›Full record

ArticleAnnals of surgical oncology2019

Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.

S Samiei, B N van Kaathoven, L Boersma, R W Y Granzier, S Siesling, S M E Engelen, L de Munck, S M J van Kuijk, R R J W van der Hulst, M B I Lobbes and 2 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05625698 (Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using MagTrace), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05625698 nacompletednot on this mapstarted 2021, after this paper: background citation

Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using MagTrace (Superparamagnetic Iron Oxide Nanoparticles, SPIO) and Magseed, in Clinically Node Negative and Node Positive Patients: a Feasibility Study.

TypeinterventionalSponsorVastra Gotaland RegionRan2021 to 2023Enrolled80ConditionsBreast CancerArmsMagTrace only, MagTrace and Magseed
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

S SamieiDepartment of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands. sanaz.samiei@mumc.nl.
B N van KaathovenDepartment of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
L BoersmaGROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.
R W Y GranzierDepartment of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
S SieslingDepartment of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
S M E EngelenDepartment of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
L de MunckDepartment of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
S M J van KuijkDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, Maastricht, The Netherlands.
R R J W van der HulstDepartment of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
M B I LobbesDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
M L SmidtDepartment of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
T J A van NijnattenDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
Maastricht University · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

KWF Kankerbestrijding UM 2013-6229
6 · The paper itself

Abstract

backgroundResidual axillary lymph node involvement after neoadjuvant systemic therapy (NST) is the determining factor for postmastectomy radiation therapy (PMRT). Preoperative identification of patients needing PMRT is essential to enable shared decision-making when choosing the optimal timing of breast reconstruction. We determined the risk of positive sentinel lymph node (SLN) after NST in clinically node-negative (cN0) breast cancer.

methodsAll cT1-3N0 patients treated with NST followed by mastectomy and SLNB between 2010 and 2016 were identified from the Netherlands Cancer Registry. Rate of positive SLN for different breast cancer subtypes was determined. Logistic regression analysis was performed to determine correlated clinicopathological variables with positive SLN.

resultsIn total 788 patients were included, of whom 25.0% (197/788) had positive SLN. cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+ , and cT1-2N0 triple-negative patients had the lowest rate of positive SLN: 7.2-11.5%, 0-6.3%, and 2.9-6.2%, respectively. cT1-3N0 ER+HER2- and cT3N0 triple-negative patients had the highest rate of positive SLN: 23.8-41.7% and 30.4%, respectively. Multivariable regression analysis showed that cT2 (odds ratio [OR] 1.93; 95% confidence interval [CI] 1.01-3.96), cT3 (OR 2.56; 95% CI 1.30-5.38), grade 3 (OR 0.44; 95% CI 0.21-0.91), and ER+HER2- subtype (OR 3.94; 95% CI 1.77-8.74) were correlated with positive SLN.

conclusionsIn cT1-3N0 ER+HER2+, cT1-3N0 ER-HER2+, and cT1-2N0 triple-negative patients treated with NST, immediate reconstruction can be considered an acceptable option due to low risk of positive SLN. In cT1-3N0 ER+HER2- and cT3N0 triple-negative patients treated with NST, risks and benefits of immediate reconstruction should be discussed with patients due to the relatively high risk of positive SLN.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMammaplastyMastectomyMiddle AgedNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID31359276
PMCPMC6787110
OpenAlexW2966576043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.